Abstract
The lung has significant susceptibility to injury from a variety of chemotherapeutic agents. The clinician must be familiar with classic chemotherapeutic agents with well-described pulmonary toxicities and must also be vigilant about a host of new agents that may exert adverse effects on lung function. The diagnosis of chemotherapy-associated lung disease remains an exclusionary process, particularly with respect to considering usual and atypical infections, as well as recurrence of the underlying neoplastic process in these immune compromised patients. In many instances, chemotherapy-associated lung disease may respond to withdrawal of the offending agent and to the judicious application of corticosteroid therapy.
MeSH terms
-
Antibiotics, Antineoplastic / adverse effects
-
Antimetabolites, Antineoplastic / adverse effects
-
Antineoplastic Agents, Phytogenic / adverse effects
-
Bleomycin / adverse effects
-
Busulfan / adverse effects
-
Camptothecin / adverse effects
-
Camptothecin / analogs & derivatives*
-
Cyclophosphamide / adverse effects
-
Humans
-
Iatrogenic Disease
-
Interferons / adverse effects
-
Irinotecan
-
Lung Diseases / chemically induced*
-
Lung Diseases / physiopathology
-
Methotrexate / adverse effects
-
Mitomycin / adverse effects
-
Nitrosamines / adverse effects
-
Respiratory Function Tests
-
Tretinoin / adverse effects
Substances
-
Antibiotics, Antineoplastic
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents, Phytogenic
-
Nitrosamines
-
Bleomycin
-
Mitomycin
-
Tretinoin
-
Irinotecan
-
Cyclophosphamide
-
Interferons
-
Busulfan
-
Camptothecin
-
Methotrexate